bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Июль 23, 2024
Both protein nanoparticle and mRNA vaccines were clinically de-risked during the COVID-19 pandemic
Язык: Английский
Current Opinion in Biotechnology, Год журнала: 2024, Номер 86, С. 103082 - 103082
Опубликована: Март 1, 2024
Язык: Английский
Процитировано
7
Journal of Medical Virology, Год журнала: 2025, Номер 97(1)
Опубликована: Янв. 1, 2025
ABSTRACT A total of 5011 adult volunteers attending vaccination centers in different regions Colombia were enrolled a 1‐year prospective observational cohort study to evaluate the immunogenicity and effectiveness SARS‐CoV‐2‐based vaccines as part National Vaccine Program established contain COVID‐19 pandemic. Following informed consent, 5,011 participants underwent sociodemographic survey PCR testing assess SARS‐CoV‐2 infection. Blood samples collected, serum fractions obtained from participant subsample ( n = 3441) at six‐time points virus‐specific IgG responses Spike protein, its Receptor Binding Domain, Nucleoprotein by ELISA. Additionally, antibody‐neutralizing activity was evaluated using cPass neutralization kit. Most (95.8%; 4802) received between one Ad26. COV2.S (Janssen vaccine) four vaccine doses BNT162b2 (Pfizer/BioNTech), AZD1222 (AstraZeneca), mRNA‐1273 (Moderna), CoronaVac (Sinovac), with some receiving combinations; small group, 4.2% 209), remained unvaccinated. Throughout study, only 8.76% 439) tested positive for PCR. Notably, all seroconverted antibodies, high seropositivity rates S (99.8%; 4795), RBD (99.7%; 1691), N (92.7%; 3072) proteins. Moreover, significant (92%–97%) neutralizing observed circulating variants. This highlights importance assessing duration response elicited infection, antibody potential surrogate marker protection. These findings provide important insight further strengthening strategies control COVID‐19.
Язык: Английский
Процитировано
0
medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown
Опубликована: Фев. 8, 2025
Abstract IMPORTANCE Prior studies have demonstrated the effectiveness of COVID-19 vaccines in children and adolescents. However, benefits vaccination these age groups with prior infection remain underexplored. OBJECTIVE To evaluate preventing reinfection various Omicron subvariants (BA.1/2, BA.4/5, XBB, later) among 5- to 17-year-olds SARS-CoV-2 infection. DESIGN A target trial emulation through nested designs distinct study periods. SETTING The utilized data from Research COVID Enhance Recovery (RECOVER) initiative, a national electronic health record (EHR) database comprising 37 U.S. children’s hospitals institutions. PARTICIPANTS Individuals aged 5-17 years documented history start date during specific variant-dominant period (Delta, BA.1/2, or BA.4/5) who received subsequent dose vaccine periods were compared those did not receive period. Those infected within Delta-Omicron composite (December 1, 2021, December 31, 2021) excluded. was January 2022, August 30, 2023, focused on adolescents 12 17 5 11 years. EXPOSURES At least one vs. no receipt any MAIN OUTCOMES AND MEASURES primary outcome is (both asymptomatic symptomatic cases). estimated as (1-hazard ratio) *100%, confounders adjusted by combination propensity score matching exact matching. RESULTS analyzed 87,573 participants BA.1/2 period, 229,326 BA.4/5 282,981 XBB later Among vaccinated individuals, significant protection observed rates 62% (95% CI: 38%-77%) for 65% 32%-81%) During 57% 25%-76%) children, but statistically (36%, 95% −16%-65%). For either group, 22% −36%-56%) 34% −10%-61%) CONCLUSIONS RELEVANCE provides against infections early mid-Omicron This also highlights importance addressing low pediatric populations enhance emerging variants. Key Points Question Does protect infection? Findings significantly reduced risk provided moderate 57%, (36%) significant. subvariants, show group. Meaning offered meaningful earlier became less effective highlighting challenges sustaining virus continues evolve.
Язык: Английский
Процитировано
0
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Фев. 25, 2025
The rapid spread of SARS-CoV-2 and its continuing impact on human health has prompted the need for effective development monoclonal antibody therapeutics. In this study, we investigate polyclonal antibodies in serum B cells from whole blood three donors with immunity to find high-affinity anti-SARS-CoV-2 escape variants. Serum IgG were selected by their affinity receptor-binding domain (RBD) non-RBD sites spike protein Omicron subvariant B.1.1.529 each donor. Antibodies analyzed bottom-up mass spectrometry, matched single- bulk-cell sequenced repertoires observed recombinantly expressed, characterized assess binding, cross-reactivity between different variants, capacity inhibit RBD binding host protein. Donors infected early subvariants had subnanomolar that also showed activity a newer BQ.1.1. convergent immune response. other sequences similar publicly reported antibodies, same variant-binding neutralization profiles as public sequences. subset cell repertoire, which demonstrates significant dynamics circulating peripheral blood.
Язык: Английский
Процитировано
0
Pathogens, Год журнала: 2024, Номер 13(12), С. 1109 - 1109
Опубликована: Дек. 15, 2024
Antibody-dependent enhancement (ADE) is a phenomenon in which antibodies enhance subsequent viral infections rather than preventing them. Sub-optimal levels of neutralizing individuals infected with dengue virus are known to be associated severe disease upon reinfection different serotype. For Severe Acute Respiratory Syndrome Coronavirus type-2 infection, three types ADE have been proposed: (1) Fc receptor-dependent infection cells expressing receptors, such as macrophages by anti-spike antibodies, (2) receptor-independent epithelial and (3) cytokine production anti-nucleocapsid antibodies. This review focuses on the induced examining its potential role COVID-19 during contribution post-acute sequelae COVID-19, i.e., prolonged symptoms lasting at least months after acute phase disease. We also discuss protective effects recently identified that neutralize Omicron variants.
Язык: Английский
Процитировано
2
Immunological Reviews, Год журнала: 2024, Номер unknown
Опубликована: Дек. 27, 2024
The SARS-CoV-2 spike (S) protein has undergone significant evolution, enhancing both receptor binding and immune evasion. In this review, we summarize ongoing efforts to develop antibodies targeting various epitopes of the S protein, focusing on their neutralization potency, breadth, escape mechanisms. Antibodies receptor-binding site (RBS) typically exhibit high neutralizing potency but are frequently evaded by mutations in variants. contrast, conserved regions, such as S2 stem helix fusion peptide, broader reactivity generally lower potency. However, several broadly have demonstrated exceptional efficacy against emerging variants, including latest omicron subvariants, underscoring potential vulnerable sites RBS-A RBS-D/CR3022. We also highlight public classes different protein. targeted present opportunities for germline-targeting vaccine strategies. Overall, developing escape-resistant, potent effective vaccines remains crucial combating future This review emphasizes importance identifying key utilizing antibody affinity maturation inform therapeutic design.
Язык: Английский
Процитировано
2
ACS Central Science, Год журнала: 2024, Номер 10(10), С. 1871 - 1884
Опубликована: Сен. 17, 2024
The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is main target neutralizing antibodies. Although they are infrequently elicited during infection or vaccination, antibodies that bind to conformation-specific cryptic face RBD display remarkable breadth binding and neutralization across
Язык: Английский
Процитировано
1
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Июнь 5, 2024
The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is main target neutralizing antibodies. Although they are infrequently elicited during infection or vaccination, antibodies that bind to conformation-specific cryptic face RBD display remarkable breadth binding and neutralization across
Язык: Английский
Процитировано
0
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Июль 23, 2024
Both protein nanoparticle and mRNA vaccines were clinically de-risked during the COVID-19 pandemic
Язык: Английский
Процитировано
0